PURPOSE: Retinal pigment epithelial (RPE) cell death is an important feature of the advanced forms of AMD. Complement alternative pathway (AP) activation is associated with RPE cell death in AMD. In this study, we developed a new model to initiate AP activation on RPE cells and investigated the cellular mechanisms modulating AP activation-mediated RPE cell death. METHODS: An anti-RPE antibody was developed. A spontaneously arising human RPE cell line (ARPE-19) and donor RPE cells were primed with this antibody followed by stimulation with 6% C1q-depleted human serum (C1q-Dep) to activate AP. Complement activation was evaluated by flow cytometry and immunofluorescent staining. Cellular response to complement activation was examined by measurement of intracellular calcium and adenosine triphosphate (ATP) release. Cell viability was assessed by Sytox orange, tetrazolium salt, and lactate dehydrogenase release assays. RESULTS: Alternative pathway complement-mediated RPE cell death was associated with membrane attack complex formation and a rapid rise in intracellular calcium followed by release of ATP. Downregulation of membrane complement regulatory proteins and protein kinase C (PKC) inhibition increased cell susceptibility to complement attack. Pretreatment of RPE cells with either hydrogen peroxide or hydroquinone enhanced cell death. Chronic repetitive treatment of RPE cells with low levels of oxidants also enhanced complement-mediated cell death. CONCLUSIONS: Activation of complement through the alternative pathway induces sublytic and lytic phases of complement attack on RPE cells, leading to cell death modulated by extracellular calcium, membrane complement regulatory proteins, and intracellular signaling mechanisms. Single-dose oxidant exposure and low-dose repetitive oxidant exposure rendered RPE cells more susceptible to complement-mediated death.
PURPOSE: Retinal pigment epithelial (RPE) cell death is an important feature of the advanced forms of AMD. Complement alternative pathway (AP) activation is associated with RPE cell death in AMD. In this study, we developed a new model to initiate AP activation on RPE cells and investigated the cellular mechanisms modulating AP activation-mediated RPE cell death. METHODS: An anti-RPE antibody was developed. A spontaneously arising human RPE cell line (ARPE-19) and donor RPE cells were primed with this antibody followed by stimulation with 6% C1q-depleted human serum (C1q-Dep) to activate AP. Complement activation was evaluated by flow cytometry and immunofluorescent staining. Cellular response to complement activation was examined by measurement of intracellular calcium and adenosine triphosphate (ATP) release. Cell viability was assessed by Sytox orange, tetrazolium salt, and lactate dehydrogenase release assays. RESULTS: Alternative pathway complement-mediated RPE cell death was associated with membrane attack complex formation and a rapid rise in intracellular calcium followed by release of ATP. Downregulation of membrane complement regulatory proteins and protein kinase C (PKC) inhibition increased cell susceptibility to complement attack. Pretreatment of RPE cells with either hydrogen peroxide or hydroquinone enhanced cell death. Chronic repetitive treatment of RPE cells with low levels of oxidants also enhanced complement-mediated cell death. CONCLUSIONS: Activation of complement through the alternative pathway induces sublytic and lytic phases of complement attack on RPE cells, leading to cell death modulated by extracellular calcium, membrane complement regulatory proteins, and intracellular signaling mechanisms. Single-dose oxidant exposure and low-dose repetitive oxidant exposure rendered RPE cells more susceptible to complement-mediated death.
Authors: Tracey A Bailey; Naheed Kanuga; Ignacio A Romero; John Greenwood; Philip J Luthert; Michael E Cheetham Journal: Invest Ophthalmol Vis Sci Date: 2004-02 Impact factor: 4.799
Authors: Susan D Vogt; Christine A Curcio; Lan Wang; Chuan-Ming Li; Gerald McGwin; Nancy E Medeiros; Nancy J Philp; James A Kimble; Russell W Read Journal: Exp Eye Res Date: 2011-06-12 Impact factor: 3.467
Authors: Anna L Fett; Manuel M Hermann; Philipp S Muether; Bernd Kirchhof; Sascha Fauser Journal: Histol Histopathol Date: 2012-03 Impact factor: 2.303
Authors: K Lueck; S Wasmuth; J Williams; T R Hughes; B P Morgan; A Lommatzsch; J Greenwood; S E Moss; D Pauleikhoff Journal: Eye (Lond) Date: 2011-05-20 Impact factor: 3.775
Authors: Nataly Strunnikova; Connie Zhang; Diane Teichberg; Scott W Cousins; Judit Baffi; Kevin G Becker; Karl G Csaky Journal: Invest Ophthalmol Vis Sci Date: 2004-10 Impact factor: 4.799
Authors: Alex Woodell; Beth Coughlin; Kannan Kunchithapautham; Sarah Casey; Tucker Williamson; W Drew Ferrell; Carl Atkinson; Bryan W Jones; Bärbel Rohrer Journal: PLoS One Date: 2013-06-25 Impact factor: 3.240
Authors: Mikhail Linetsky; Karina S Bondelid; Sofiya Losovskiy; Vadym Gabyak; Mario J Rullo; Thomas I Stiadle; Vasu Munjapara; Priyali Saxena; Duoming Ma; Yu-Shiuan Cheng; Andrew M Howes; Emeka Udeigwe; Robert G Salomon Journal: Chem Res Toxicol Date: 2018-07-09 Impact factor: 3.739
Authors: Brandon P Lucke-Wold; Ryan C Turner; Aric F Logsdon; James W Simpkins; Daniel L Alkon; Kelly E Smith; Yi-Wen Chen; Zhenjun Tan; Jason D Huber; Charles L Rosen Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Ana Lucia Marques Ventura; Alexandre Dos Santos-Rodrigues; Claire H Mitchell; Maria Paula Faillace Journal: Brain Res Bull Date: 2018-11-17 Impact factor: 4.077
Authors: SriniVas R Sadda; Usha Chakravarthy; David G Birch; Giovanni Staurenghi; Erin C Henry; Christopher Brittain Journal: Retina Date: 2016-10 Impact factor: 4.256
Authors: Hui Shi; Jennifer A E Williams; Li Guo; Dimitrios Stampoulis; M Francesca Cordeiro; Stephen E Moss Journal: Apoptosis Date: 2015-04 Impact factor: 4.677
Authors: Ping Yang; Nikolai P Skiba; Grace M Tewkesbury; Victoria M Treboschi; Peter Baciu; Glenn J Jaffe Journal: Invest Ophthalmol Vis Sci Date: 2017-06-01 Impact factor: 4.799